$447.18
1.48% yesterday
Nasdaq, May 20, 10:06 pm CET
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Vertex Pharmaceuticals Stock price

$447.18
-30.34 6.35% 1M
-4.05 0.90% 6M
+44.48 11.05% YTD
+1.31 0.29% 1Y
+188.59 72.93% 3Y
+162.56 57.11% 5Y
+320.43 252.80% 10Y
Nasdaq, Closing price Tue, May 20 2025
+6.52 1.48%
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Key metrics

Market capitalization $114.83b
Enterprise Value $110.27b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.99
P/S ratio (TTM) P/S ratio 10.40
P/B ratio (TTM) P/B ratio 6.97
Revenue growth (TTM) Revenue growth 8.55%
Revenue (TTM) Revenue $11.04b
EBIT (operating result TTM) EBIT $-330.40m
Free Cash Flow (TTM) Free Cash Flow $-1.25b
Cash position $6.21b
EPS (TTM) EPS $-3.92
P/E forward 29.48
P/S forward 9.63
EV/Sales forward 9.24
Short interest 1.66%
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Vertex Pharmaceuticals forecast:

18x Buy
51%
15x Hold
43%
2x Sell
6%

Analyst Opinions

35 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
51%
Hold
43%
Sell
6%

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
11,043 11,043
9% 9%
100%
- Direct Costs 1,551 1,551
16% 16%
14%
9,492 9,492
7% 7%
86%
- Selling and Administrative Expenses 1,317 1,317
26% 26%
12%
- Research and Development Expense 8,305 8,305
141% 141%
75%
-130 -130
103% 103%
-1%
- Depreciation and Amortization 201 201
2% 2%
2%
EBIT (Operating Income) EBIT -330 -330
108% 108%
-3%
Net Profit -989 -989
125% 125%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Neutral
Investors Business Daily
one day ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
Business Wire
5 days ago
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in the Evercore Biotechnology Summit on Wednesday, May 21, 2025. Dr. Reshma Kewalramani, Chief Executive Office...
Neutral
MarketBeat
8 days ago
The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector.
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 6,100
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today